Purohit S, Ferris DG, Alvarez M, et al. - Researchers measured anti-glycan antibodies (AGA) in cervical cancer (CC) patient sera and evaluated their influence on treatment outcome. Participants were 276 stage II and 292 stage III Peruvian CC patients, in whom, serum AGA was measured by utilizing a high content and throughput Luminex multiplex glycan array including 177 glycans. They employed Cox regression in order to determine the link with disease-specific survival (DSS) and progression free survival (PFS). Findings revealed that cervical cancer patients that were positive for particular antiglycan antibodies and received brachytherapy experienced a better PFS and DSS. Those who were positive for AGA against multiple glycans pertaining to the blood group H, Lewis, Ganglio, Isoglobo, lacto and sialylated tetrarose antigens, were shown to have better PFS and DSS.